Vyleesi (autoinjector)?

Question

Accepted Answer

Vyleesi (difelikefalin) – Autoinjector

Feature	Detail
Indication	Chronic pruritus (itching) in patients receiving maintenance hemodialysis.
Formulation	0.2 mg/mL solution in a pre‑filled autoinjector.
Mechanism of Action	Selective κ‑opioid receptor agonist that acts peripherally (no central nervous system penetration). It dampens itch signaling pathways in the skin and nerves without the typical opioid side‑effects.
Administration	• Route: Subcutaneous injection. • Frequency: 0.2 mg once daily. • Device: A ready‑to‑use, single‑use autoinjector that delivers the dose with a single push. • Technique: Inject into the thigh or abdomen, rotating sites to avoid irritation.
Dosing & Use	• Each autoinjector contains 2 mL of solution (0.4 mg total). Use 1 mL (0.2 mg) per dose. • Do not exceed 0.2 mg per day. • If a dose is missed, skip it and resume the next scheduled dose.
Common Side Effects	Injection‑site reactions (redness, swelling, pain), dizziness, mild headache, and nausea. These are usually transient.
Serious/Important Concerns	• Rare hypersensitivity reactions (rash, itching, swelling of lips/face). • No known drug‑drug interactions with dialysis. • Not recommended for patients with a history of severe allergic reactions to the drug or its excipients.
Contraindications	• Hypersensitivity to difelikefalin or any component of the formulation.
Precautions	• Use a new autoinjector for each dose; never reuse. • Store at room temperature (15–30 °C) and protect from light. • Keep away from children.
Drug Interactions	No clinically significant interactions reported. However, concomitant use with other opioid agents is not contraindicated but monitoring for additive effects is prudent (though peripheral action reduces CNS risk).
Pregnancy & Lactation	Limited data; use only if clearly needed and after discussing potential risks with a healthcare provider.
Patient Counseling Points	• Wash hands before use. • Inject into a clean area of skin. • Observe injection site for reactions. • Report severe or persistent itching, rash, or breathing difficulty to a clinician immediately.
Clinical Summary	Clinical trials showed that Vyleesi reduced itch severity scores by ~40% compared with placebo in patients on hemodialysis. It’s the only FDA‑approved drug specifically targeting chronic pruritus in this population.

How to Use the Autoinjector

Check the date on the package. Use before the expiration date.
Hold the device with the needle tip pointing up.
Insert the needle into the thigh or abdomen at a 90° angle.
Press the trigger firmly until you hear a click; the dose is delivered automatically.
Remove the needle and discard the autoinjector in a puncture‑proof container.

If you’re new to autoinjectors, a nurse or dialysis staff member can give a quick demonstration.

When to Seek Medical Attention

Severe allergic reactions (difficulty breathing, swelling of face/lips).
Persistent or worsening itching despite treatment.
New, unexplained skin rash or swelling at the injection site.
Any other concerning symptoms.

Disclaimer:
This information is for educational purposes only and is not a substitute for personalized medical advice. Always consult your prescribing clinician or pharmacist for specific guidance about your health condition and medication regimen.

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Vyleesi (autoinjector)?

How to Use the Autoinjector

When to Seek Medical Attention